US 11,986,500 B2
Bacteriotherapy for clostridium difficile colitis
Edwin J. Hlavka, Minneapolis, MN (US)
Assigned to REBIOTIX INC, Roseville, MN (US)
Filed by Rebiotix, Inc., Roseville, MN (US)
Filed on Dec. 18, 2023, as Appl. No. 18/544,083.
Application 18/544,083 is a continuation of application No. 17/886,274, filed on Aug. 11, 2022, granted, now 11,944,654.
Application 17/886,274 is a continuation of application No. 15/964,228, filed on Apr. 27, 2018, granted, now 11,446,337.
Application 15/964,228 is a continuation of application No. 15/251,725, filed on Aug. 30, 2016, abandoned.
Application 15/251,725 is a continuation of application No. 14/093,913, filed on Dec. 2, 2013, granted, now 9,463,208.
Application 14/093,913 is a continuation of application No. 13/576,573, granted, now 9,629,881, previously published as PCT/US2011/000184, filed on Feb. 1, 2011.
Claims priority of provisional application 61/351,184, filed on Jun. 3, 2010.
Claims priority of provisional application 61/337,283, filed on Feb. 1, 2010.
Prior Publication US 2024/0122995 A1, Apr. 18, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/741 (2015.01); A61K 9/20 (2006.01); A61K 35/74 (2015.01); C12N 1/04 (2006.01); C12N 1/20 (2006.01); G01N 33/569 (2006.01)
CPC A61K 35/741 (2013.01) [A61K 9/20 (2013.01); A61K 35/74 (2013.01); C12N 1/04 (2013.01); C12N 1/20 (2013.01); G01N 33/56911 (2013.01); G01N 2333/33 (2013.01); G01N 2800/52 (2013.01)] 24 Claims
 
1. A fecal microbiota composition, comprising:
a processed fecal sample obtained from a human donor, and
a cryoprotectant.